Attention-deficit/Hyperactivity Disorder
Conditions
Brief summary
The primary objective of this study is to evaluate the long-term maintenance of efficacy of Extended-Release Guanfacine HCl in children and adolescents (6-17 years) with attention-deficit/hyperactivity disorder (ADHD) who respond to an initial open-label, short term treatment with SPD503.
Interventions
The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
OTHERPlacebo
Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
Sponsors
Shire
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, aged 6-17 years at the time of consent/assent at Screening/Visit 1. 2. Subject's parent or legally authorised representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 (1996) and applicable regulations before completing any study-related procedures at Screening/Visit 1. 3. Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD, combined subtype, hyperactive/impulsive subtype, or inattentive sub-type based on a detailed psychiatric evaluation using the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL). 4. Subject has a minimum ADHD-RS-IV total score of 32 at Enrolment/Visit 2. 5. Subject has a minimum CGI-S score of 4 at Enrolment/Visit 2. 6. Subject is functioning at an age-appropriate level intellectually, as deemed by the Investigator. 7. Subject and parent/LAR understand, are willing, able, and likely to fully comply with the study requirements, procedures, and restrictions defined in this protocol. 8. Subject is able to swallow intact tablets. 9. Subject who is a female of child-bearing potential (FOCP), defined as 9 years of age or \<9 years of age and is post-menarchal, must have a negative serum beta Human Chorionic Gonadotropin (hCG) pregnancy test at Screening/Visit 1 and a negative urine pregnancy test at Enrolment/Visit 2 and agree to comply with any applicable contraceptive requirements of the protocol. 10. Subject has a supine and standing BP measurement within the 95th percentile for age, gender, and height.
Exclusion criteria
1. Subject has a current, controlled (requiring a prohibited medication or behavioural modification program) or uncontrolled, comorbid psychiatric diagnosis, except oppositional defiant disorder (ODD), including any severe comorbid Axis II disorders or severe Axis I disorders such as post traumatic stress disorder, bipolar illness, psychosis, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse disorder, or other symptomatic manifestations or lifetime history of bipolar illness, psychosis, or conduct disorder that, in the opinion of the Investigator, contraindicate SPD503 treatment or confound efficacy or safety assessments. 2. Subject has any condition or illness including clinically significant abnormal Screening/Visit 1 laboratory values which, in the opinion of the Investigator, represents an inappropriate risk to the subject and/or could confound the interpretation of the study. 3. Subject has a known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems (e.g., clinically significant heart block), exercise-related cardiac events including syncope and pre syncope, or clinically significant bradycardia. 4. Subject with orthostatic hypotension or a known history of controlled or uncontrolled hypertension. 5. Subject has clinically significant ECG findings as judged by the Investigator with consideration of the central ECG laboratory's interpretation. 6. Current use of any prohibited medication or other medications, including herbal supplements, that affect BP or heart rate or that have CNS effects or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (inhaled bronchodilators are permitted) or a history of chronic use of sedating medications \[i.e., antihistamines\]) in violation of the protocol specified washout criteria at Enrolment/Visit 2. 7. Subject has used an investigational product within 30 days prior to Enrolment/Visit 2. 8. Subject is significantly overweight based on Centre for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts. Significantly overweight is defined as a BMI \>95th percentile. 9. Children aged 6-12 years with a body weight of \<25kg or adolescents aged 13-17 years with a body weight of \<34kg or \>91kg at Screening/Visit 1. 10. Subject has a known or suspected allergy, hypersensitivity, or clinically significant intolerance to guanfacine hydrochloride or any components found in SPD503. 11. Clinically important abnormality on drug and alcohol screen (excluding the subject's current ADHD stimulant if applicable) at Screening/Visit 1. 12. Subject has a history of alcohol or other substance abuse or dependence, as defined by DSM-IV-TR (with the exception of nicotine) within the last 6 months. 13. Subject is female and is pregnant or currently lactating. 14. Subject failed screening or was previously enrolled in this study. 15. Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator (see protocol Section 7.2.4.2 for additional guidance). 16. History of failure to respond to an adequate trial of an alpha 2-agonist for the treatment of ADHD (consisting of an appropriate dose and adequate duration of therapy in the opinion of the Investigator). 17. Subject has a history of a seizure disorder (other than a single childhood febrile seizure occurring before the age of 3 years) or the presence of a serious tic disorder (including Tourette's syndrome). 18. Subject has another member of the same household currently participating in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Treatment Failures During the Double-Blind Randomized-Withdrawal Phase | 26 weeks | Treatment failure was defined as \>= 50% increase (worsening) in ADHD-RS-IV total score and a \>= 2 point increase (worsening) in CGI-S score compared with the respective scores at the Double-blind Randomized-withdrawal Baseline Visit at 2 consecutive Double-blind Randomized-withdrawal Phase visits. Subjects meeting these criteria were regarded as treatment failures regardless of whether or not they were withdrawn. All subjects who discontinued the study for any reason were regarded as treatment failures for the primary analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Double-Blind Randomized-Withdrawal Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 26 of the Double-Blind Randomized-Withdrawal Phase - Last Observation Carried Forward (LOCF) | Baseline and week 26 | The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. |
| Percent of Subjects With an Assessment of Normal/Borderline Mentally Ill on Clinical Global Impression-Severity of Illness (CGI-S) Scale During the Double-Blind Randomized-Withdrawal Phase - LOCF | 26 weeks | CGI-S assesses the severity of the subject's condition on a 7-point scale: 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill) |
| Change From Double-Blind Randomized-Withdrawal Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Week 26 of the Double-Blind Randomized-Withdrawal Phase - LOCF | Baseline and week 26 | The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment. |
| Health Utilities Index-2/3 (HUI 2/3) Scores During the Double-Blind Randomized-Withdrawal Phase - LOCF | 26 weeks | HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. |
| Columbia-Suicide Severity Rating Scale During Double-Blind Randomized-Withdrawal Phase | 26 weeks | C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. |
| Change From Open-Label Baseline in ADHD-RS-IV Total Score at Week 13 of the Open-Label Phase - LOCF | Baseline and 13 weeks | The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. |
| Time to Treatment Failure During the Double-Blind Randomized-Withdrawal Phase | 26 weeks | Treatment failure was defined as \>= 50% increase (worsening) in ADHD-RS-IV total score and a \>= 2 point increase (worsening) in CGI-S score compared with the respective scores at the Double-blind Randomized-withdrawal Baseline Visit at 2 consecutive Double-blind Randomized-withdrawal Phase visits. Subjects meeting these criteria were regarded as treatment failures regardless of whether or not they were withdrawn. All subjects who discontinued the study for any reason were regarded as treatment failures for the primary analysis. |
| Percent of Subjects With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores During Open-Label Phase - LOCF | 13 weeks | Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. |
| Percent of Subjects With an Assessment of Normal/Borderline Mentally Ill on CGI-S Scale During the Open-Label Phase - LOCF | 13 weeks | CGI-S assesses the severity of the subject's condition on a 7-point scale: 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill) |
| Change From Open-Label Baseline in WFIRS-P Global Score at Week 13 of the Open-Label Phase - LOCF | Baseline and week 13 | The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment. |
| HUI 2/3 Scores During the Open-Label Phase - LOCF | 13 weeks | HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. |
| Columbia-Suicide Severity Rating Scale During Open-Label Phase | 13 weeks | C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. |
| Percentage of Responders in the Open-Label Phase - LOCF | 13 weeks | Response is defined as a percentage decrease (improvement) from Baseline in the ADHD-RS-IV total score of \>=30% and a CGI-S score of 1 or 2. |
Countries
Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Guanfacine Hydrochloride Administered as a once-daily oral dose between 1-7mg/day depending on age and weight | 526 |
| Total | 526 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Double-Blind Randomized-Withdrawal Phase | Adverse Event | 3 | 2 |
| Double-Blind Randomized-Withdrawal Phase | Lack of Efficacy | 13 | 20 |
| Double-Blind Randomized-Withdrawal Phase | Lost to Follow-up | 3 | 2 |
| Double-Blind Randomized-Withdrawal Phase | Other | 4 | 3 |
| Double-Blind Randomized-Withdrawal Phase | Protocol Violation | 1 | 0 |
| Double-Blind Randomized-Withdrawal Phase | Treatment failure criteria met | 47 | 71 |
| Double-Blind Randomized-Withdrawal Phase | Withdrawal by Subject | 10 | 8 |
| Open-Label Phase | Adverse Event | 42 | 0 |
| Open-Label Phase | Lack of Efficacy | 56 | 0 |
| Open-Label Phase | Lost to Follow-up | 11 | 0 |
| Open-Label Phase | Other | 12 | 0 |
| Open-Label Phase | Protocol Violation | 4 | 0 |
| Open-Label Phase | Response criteria not met | 46 | 0 |
| Open-Label Phase | Withdrawal by Subject | 41 | 0 |
Baseline characteristics
| Characteristic | Guanfacine Hydrochloride |
|---|---|
| Age, Continuous | 10.7 Years STANDARD_DEVIATION 2.7 |
| Age, Customized 13-17 years | 135 Participants |
| Age, Customized 6-12 years | 391 Participants |
| Region of Enrollment BELGIUM | 19 Participants |
| Region of Enrollment CANADA | 30 Participants |
| Region of Enrollment FRANCE | 14 Participants |
| Region of Enrollment GERMANY | 27 Participants |
| Region of Enrollment ITALY | 31 Participants |
| Region of Enrollment NETHERLANDS | 29 Participants |
| Region of Enrollment SPAIN | 68 Participants |
| Region of Enrollment SWEDEN | 5 Participants |
| Region of Enrollment UNITED KINGDOM | 25 Participants |
| Region of Enrollment UNITED STATES | 278 Participants |
| Sex: Female, Male Female | 130 Participants |
| Sex: Female, Male Male | 396 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 423 / 526 | 51 / 158 | 65 / 157 |
| serious Total, serious adverse events | 5 / 526 | 4 / 158 | 2 / 157 |
Outcome results
Primary
Percentage of Participants With Treatment Failures During the Double-Blind Randomized-Withdrawal Phase
Treatment failure was defined as \>= 50% increase (worsening) in ADHD-RS-IV total score and a \>= 2 point increase (worsening) in CGI-S score compared with the respective scores at the Double-blind Randomized-withdrawal Baseline Visit at 2 consecutive Double-blind Randomized-withdrawal Phase visits. Subjects meeting these criteria were regarded as treatment failures regardless of whether or not they were withdrawn. All subjects who discontinued the study for any reason were regarded as treatment failures for the primary analysis.
Time frame: 26 weeks
Population: Randomized Full Analysis Set (FAS) defined as all subjects who were randomized and took at least 1 dose of investigational product during the Double-blind Randomized-withdrawal Phase. Subjects from Site 801 were excluded from the Randomized FAS.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Treatment Failures During the Double-Blind Randomized-Withdrawal Phase | 64.9 percentage of treatment failures |
| Guanfacine Hydrochloride | Percentage of Participants With Treatment Failures During the Double-Blind Randomized-Withdrawal Phase | 49.3 percentage of treatment failures |
p-value: 0.00695% CI: [-26.6, -4.5]Cochran-Mantel-Haenszel
Secondary
Change From Double-Blind Randomized-Withdrawal Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 26 of the Double-Blind Randomized-Withdrawal Phase - Last Observation Carried Forward (LOCF)
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
Time frame: Baseline and week 26
Population: Randomized FAS
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Double-Blind Randomized-Withdrawal Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 26 of the Double-Blind Randomized-Withdrawal Phase - Last Observation Carried Forward (LOCF) | 15.89 units on a scale | Standard Error 1.225 |
| Guanfacine Hydrochloride | Change From Double-Blind Randomized-Withdrawal Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 26 of the Double-Blind Randomized-Withdrawal Phase - Last Observation Carried Forward (LOCF) | 9.64 units on a scale | Standard Error 1.21 |
p-value: <0.00195% CI: [-9.01, -3.48]ANCOVA
Secondary
Change From Double-Blind Randomized-Withdrawal Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Week 26 of the Double-Blind Randomized-Withdrawal Phase - LOCF
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
Time frame: Baseline and week 26
Population: Randomized FAS
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Double-Blind Randomized-Withdrawal Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Week 26 of the Double-Blind Randomized-Withdrawal Phase - LOCF | 0.23 units on a scale | Standard Error 0.036 |
| Guanfacine Hydrochloride | Change From Double-Blind Randomized-Withdrawal Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Week 26 of the Double-Blind Randomized-Withdrawal Phase - LOCF | 0.16 units on a scale | Standard Error 0.035 |
p-value: 0.11895% CI: [-0.14, 0.02]ANCOVA
Secondary
Change From Open-Label Baseline in ADHD-RS-IV Total Score at Week 13 of the Open-Label Phase - LOCF
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
Time frame: Baseline and 13 weeks
Population: Open-label Full Analysis Set (FAS) defined as all subjects who took at least 1 dose of any investigational product during the study. The Subjects from Site 801 were excluded from the Open-label FAS.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Open-Label Baseline in ADHD-RS-IV Total Score at Week 13 of the Open-Label Phase - LOCF | -25.2 units on a scale | Standard Deviation 11.97 |
p-value: <0.001t-test, 2 sided
Secondary
Change From Open-Label Baseline in WFIRS-P Global Score at Week 13 of the Open-Label Phase - LOCF
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
Time frame: Baseline and week 13
Population: Open-label FAS
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Open-Label Baseline in WFIRS-P Global Score at Week 13 of the Open-Label Phase - LOCF | -0.35 units on a scale | Standard Deviation 0.414 |
p-value: <0.001t-test, 2 sided
Secondary
Columbia-Suicide Severity Rating Scale During Double-Blind Randomized-Withdrawal Phase
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: 26 weeks
Population: Randomized Safety Population defined as all subjects who were randomized and who took at least 1 dose of investigational product during the Double-blind Randomized-withdrawal Phase.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Columbia-Suicide Severity Rating Scale During Double-Blind Randomized-Withdrawal Phase | Suicidal ideation | 2 participants |
| Placebo | Columbia-Suicide Severity Rating Scale During Double-Blind Randomized-Withdrawal Phase | Suicidal behavior | 0 participants |
| Guanfacine Hydrochloride | Columbia-Suicide Severity Rating Scale During Double-Blind Randomized-Withdrawal Phase | Suicidal ideation | 2 participants |
| Guanfacine Hydrochloride | Columbia-Suicide Severity Rating Scale During Double-Blind Randomized-Withdrawal Phase | Suicidal behavior | 0 participants |
Secondary
Columbia-Suicide Severity Rating Scale During Open-Label Phase
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: 13 weeks
Population: Open-label Safety Population defined as all subjects who took at least 1 dose of any investigational product during the study.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Columbia-Suicide Severity Rating Scale During Open-Label Phase | Suicidal ideation | 1 participants |
| Placebo | Columbia-Suicide Severity Rating Scale During Open-Label Phase | Suicidal behavior | 2 participants |
Secondary
Health Utilities Index-2/3 (HUI 2/3) Scores During the Double-Blind Randomized-Withdrawal Phase - LOCF
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
Time frame: 26 weeks
Population: Randomized FAS
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Health Utilities Index-2/3 (HUI 2/3) Scores During the Double-Blind Randomized-Withdrawal Phase - LOCF | 0.899 units on a scale | Standard Deviation 0.1272 |
| Guanfacine Hydrochloride | Health Utilities Index-2/3 (HUI 2/3) Scores During the Double-Blind Randomized-Withdrawal Phase - LOCF | 0.900 units on a scale | Standard Deviation 0.1229 |
Secondary
HUI 2/3 Scores During the Open-Label Phase - LOCF
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
Time frame: 13 weeks
Population: Open-label FAS
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | HUI 2/3 Scores During the Open-Label Phase - LOCF | 0.892 units on a scale | Standard Deviation 0.123 |
Secondary
Percentage of Responders in the Open-Label Phase - LOCF
Response is defined as a percentage decrease (improvement) from Baseline in the ADHD-RS-IV total score of \>=30% and a CGI-S score of 1 or 2.
Time frame: 13 weeks
Population: Open-label FAS
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Responders in the Open-Label Phase - LOCF | 68.6 percentage of participants |
Secondary
Percent of Subjects With an Assessment of Normal/Borderline Mentally Ill on CGI-S Scale During the Open-Label Phase - LOCF
CGI-S assesses the severity of the subject's condition on a 7-point scale: 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill)
Time frame: 13 weeks
Population: Open-label FAS
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percent of Subjects With an Assessment of Normal/Borderline Mentally Ill on CGI-S Scale During the Open-Label Phase - LOCF | 68.9 percentage of participants |
Secondary
Percent of Subjects With an Assessment of Normal/Borderline Mentally Ill on Clinical Global Impression-Severity of Illness (CGI-S) Scale During the Double-Blind Randomized-Withdrawal Phase - LOCF
CGI-S assesses the severity of the subject's condition on a 7-point scale: 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill)
Time frame: 26 weeks
Population: Randomized FAS
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percent of Subjects With an Assessment of Normal/Borderline Mentally Ill on Clinical Global Impression-Severity of Illness (CGI-S) Scale During the Double-Blind Randomized-Withdrawal Phase - LOCF | 32.5 percentage of subjects |
| Guanfacine Hydrochloride | Percent of Subjects With an Assessment of Normal/Borderline Mentally Ill on Clinical Global Impression-Severity of Illness (CGI-S) Scale During the Double-Blind Randomized-Withdrawal Phase - LOCF | 50.0 percentage of subjects |
p-value: 0.00195% CI: [6.6, 28.5]Cochran-Mantel-Haenszel
Secondary
Percent of Subjects With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores During Open-Label Phase - LOCF
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: 13 weeks
Population: Open-label FAS
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percent of Subjects With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores During Open-Label Phase - LOCF | 76.1 percentage of participants |
Secondary
Time to Treatment Failure During the Double-Blind Randomized-Withdrawal Phase
Treatment failure was defined as \>= 50% increase (worsening) in ADHD-RS-IV total score and a \>= 2 point increase (worsening) in CGI-S score compared with the respective scores at the Double-blind Randomized-withdrawal Baseline Visit at 2 consecutive Double-blind Randomized-withdrawal Phase visits. Subjects meeting these criteria were regarded as treatment failures regardless of whether or not they were withdrawn. All subjects who discontinued the study for any reason were regarded as treatment failures for the primary analysis.
Time frame: 26 weeks
Population: Randomized FAS
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Treatment Failure During the Double-Blind Randomized-Withdrawal Phase | 56.0 Days |
| Guanfacine Hydrochloride | Time to Treatment Failure During the Double-Blind Randomized-Withdrawal Phase | 218.0 Days |
p-value: 0.003Log Rank